HC Wainwright Issues Pessimistic Forecast for Voyager Therapeutics (NASDAQ:VYGR) Stock Price

Voyager Therapeutics (NASDAQ:VYGR) had its target price reduced by analysts at HC Wainwright from $30.00 to $25.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 491.72% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a research note on Tuesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $12.12.

Voyager Therapeutics Trading Down 0.8%

NASDAQ:VYGR traded down $0.04 on Wednesday, reaching $4.23. The stock had a trading volume of 164,834 shares, compared to its average volume of 571,643. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $7.44. The stock has a market cap of $234.36 million, a P/E ratio of -1.96 and a beta of 0.95. The company has a 50-day moving average of $4.54 and a 200 day moving average of $3.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.06. The firm had revenue of $13.37 million during the quarter, compared to analyst estimates of $7.86 million. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 46.59%. On average, equities analysts predict that Voyager Therapeutics will post -0.91 EPS for the current year.

Insider Activity

In other news, CFO Nathan D. Jorgensen sold 7,666 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total transaction of $36,643.48. Following the sale, the chief financial officer directly owned 123,834 shares of the company’s stock, valued at $591,926.52. This represents a 5.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently made changes to their positions in the company. Strs Ohio acquired a new position in Voyager Therapeutics during the 1st quarter valued at about $256,000. Nuveen LLC bought a new stake in shares of Voyager Therapeutics during the first quarter worth approximately $368,000. American Century Companies Inc. raised its stake in shares of Voyager Therapeutics by 7.2% during the first quarter. American Century Companies Inc. now owns 131,521 shares of the company’s stock worth $445,000 after buying an additional 8,795 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in Voyager Therapeutics by 74.0% in the first quarter. Hsbc Holdings PLC now owns 67,903 shares of the company’s stock valued at $229,000 after buying an additional 28,878 shares during the period. Finally, CWM LLC boosted its stake in Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $35,000 after acquiring an additional 9,376 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.